{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:12:18Z","timestamp":1769757138818,"version":"3.49.0"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,5,18]]},"DOI":"10.18632\/oncotarget.25341","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T09:24:15Z","timestamp":1526635455000},"page":"25101-25114","source":"Crossref","is-referenced-by-count":8,"title":["Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib"],"prefix":"10.18632","volume":"9","author":[{"given":"Kwai Fung","family":"Hui","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po Ling","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kam Pui","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Kwok Shing","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kieff","year":"2015","journal-title":"Exp Mol Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1128\/JVI.03003-12","article-title":"Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature","volume":"87","author":"Bell","year":"2013","journal-title":"J Virol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2010-05-285791","article-title":"Lymphomas differ in their dependence on Epstein-Barr virus","volume":"117","author":"Sugden","year":"2011","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1200\/JCO.2005.08.074","article-title":"Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation","volume":"23","author":"Lynch","year":"2005","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Trappe","year":"2007","journal-title":"Ann Hematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Heslop","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.chom.2010.11.004","article-title":"An ATM\/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells","volume":"8","author":"Tainter","year":"2010","journal-title":"Cell Host Microbe"},{"key":"8","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI58092","article-title":"EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors","volume":"122","author":"Nourse","year":"2012","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"crossref","first-page":"e1003314","DOI":"10.1371\/journal.ppat.1003314","article-title":"The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8","volume":"9","author":"Robertson","year":"2013","journal-title":"PLoS Pathog"},{"key":"10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/sj.onc.1207253","article-title":"The EBNA-3 gene family proteins disrupt the G2\/M checkpoint","volume":"23","author":"Gabrielli","year":"2004","journal-title":"Oncogene"},{"key":"11","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1128\/JVI.00053-07","article-title":"The ATM\/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2\/M cell cycle block","volume":"81","author":"Robertson","year":"2007","journal-title":"J Virol"},{"key":"12","doi-asserted-by":"crossref","first-page":"e1000492","DOI":"10.1371\/journal.ppat.1000492","article-title":"Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim","volume":"5","author":"Allday","year":"2009","journal-title":"PLoS Pathog"},{"key":"13","doi-asserted-by":"crossref","first-page":"e1004304","DOI":"10.1371\/journal.ppat.1004304","article-title":"EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation","volume":"10","author":"Robertson","year":"2014","journal-title":"PLoS Pathog"},{"key":"14","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1128\/JVI.73.7.5688-5697.1999","article-title":"Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription","volume":"73","author":"Allday","year":"1999","journal-title":"J Virol"},{"key":"15","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/JVI.77.7.4261-4272.2003","article-title":"Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines","volume":"77","author":"Robertson","year":"2003","journal-title":"J Virol"},{"key":"16","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Wang","year":"2015","journal-title":"Molecules"},{"key":"17","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24945","article-title":"Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death","volume":"126","author":"Chiang","year":"2010","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.27439","article-title":"Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma","volume":"131","author":"Chiang","year":"2012","journal-title":"Int J Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir","volume":"138","author":"Chiang","year":"2016","journal-title":"Int J Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Marks","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"21","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1002\/ijc.28924","article-title":"Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism","volume":"135","author":"Chiang","year":"2014","journal-title":"Int J Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Grant","year":"2004","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1535-7163.MCT-12-0811","article-title":"Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus","volume":"12","author":"Chiang","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"24","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.18632\/oncotarget.6601","article-title":"Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib","volume":"7","author":"Chiang","year":"2016","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.3390\/v9110352","article-title":"Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors","volume":"9","author":"Chiang","year":"2017","journal-title":"Viruses"},{"key":"26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.13089","article-title":"Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines","volume":"167","author":"Chiang","year":"2014","journal-title":"Br J Haematol"},{"key":"27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/mc.21835","article-title":"Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage","volume":"52","author":"Pollack","year":"2013","journal-title":"Mol Carcinog"},{"key":"28","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1158\/1535-7163.MCT-14-0220","article-title":"andinteractions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells","volume":"13","author":"Grant","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.febslet.2008.06.048","article-title":"Abrogation of G2\/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis","volume":"582","author":"Zhuang","year":"2008","journal-title":"FEBS Lett"},{"key":"30","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/stem.123","article-title":"Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G(2) but not G(1) cell cycle arrest in pluripotent human embryonic stem cells","volume":"27","author":"Navara","year":"2009","journal-title":"Stem Cells"},{"key":"31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2011.08.022","article-title":"Chk2-mediated G2\/M cell cycle arrest maintains radiation resistance in malignant meningioma cells","volume":"313","author":"Rao","year":"2011","journal-title":"Cancer Lett"},{"key":"32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.onc.1210668","article-title":"Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma","volume":"27","author":"Allday","year":"2008","journal-title":"Oncogene"},{"key":"33","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1128\/JVI.79.16.10709-10717.2005","article-title":"Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis","volume":"79","author":"Rickinson","year":"2005","journal-title":"J Virol"},{"key":"34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1128\/JVI.01096-06","article-title":"Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells","volume":"81","author":"Allday","year":"2007","journal-title":"J Virol"},{"key":"35","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.ppat.1001275","article-title":"Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1","volume":"7","author":"Robertson","year":"2011","journal-title":"PLoS Pathog"},{"key":"36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/fmb.12.147","article-title":"Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis","volume":"8","author":"Robertson","year":"2013","journal-title":"Future Microbiol"},{"key":"37","first-page":"3188","article-title":"Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells","volume":"61","author":"Monden","year":"2001","journal-title":"Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood-2006-07-037671","article-title":"Targeting aurora kinases as therapy in multiple myeloma","volume":"109","author":"Lichtenstein","year":"2007","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2015.08.015","article-title":"Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair","volume":"369","author":"Jiang","year":"2015","journal-title":"Cancer Lett"},{"key":"40","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","article-title":"Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway","volume":"385","author":"Stankovic","year":"2015","journal-title":"Lancet (London, England)"},{"key":"41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrc2169","article-title":"CDC25 phosphatases in cancer cells: key players? Good targets?","volume":"7","author":"Ducommun","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.semcancer.2006.03.002","article-title":"14-3-3 proteins in cell cycle regulation","volume":"16","author":"Benzinger","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/ncb994","article-title":"Dual phosphorylation controls Cdc25 phosphatases and mitotic entry","volume":"5","author":"Fornace","year":"2003","journal-title":"Nat Cell Biol"},{"key":"44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.embor.embor887","article-title":"Regulating mammalian checkpoints through Cdc25 inactivation","volume":"4","author":"Draetta","year":"2003","journal-title":"EMBO Rep"},{"key":"45","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216","volume":"277","author":"Piwnica-Worms","year":"1997","journal-title":"Science"},{"key":"46","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.18632\/oncotarget.2720","article-title":"Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma","volume":"6","author":"Zinzani","year":"2015","journal-title":"Oncotarget"},{"key":"47","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Egorin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"48","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Palumbo","year":"2013","journal-title":"Lancet Oncol"},{"key":"49","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6605954","article-title":"Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy","volume":"103","author":"Tobinai","year":"2010","journal-title":"Br J Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T21:26:39Z","timestamp":1720301199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":49,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2018,5,18]]}},"alternative-id":["25341","29861856"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25341","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]}}}